Semax & Selank: The Gold Standard of Nasal Nootropics
Semax and Selank are synthetic peptides approved as prescription medications in Russia and used as the most effective nasal nootropic combination available. Semax drives cognitive performance via BDNF; Selank provides anxiolysis without sedation. Together they produce a balanced flow state.
Evidence strength
Level 3
Case-control study
Peer-reviewed refs
3
Reading time
12 min
Key Takeaways
- Semax modulates BDNF and NGF gene expression in the brain — BDNF is the key molecule for neuroplasticity, learning, and neuroprotection.
- Selank provides genuine anxiolysis (GABA modulation) without sedation, cognitive impairment, or addiction potential — advantages over all benzodiazepine alternatives.
- The combination produces complementary effects: Semax drives focus and cognitive drive; Selank prevents anxiety and cortisol elevation from undermining it.
- Tolerance develops with daily Semax use — cycle 2-4 weeks on, 1-2 weeks off. Selank has minimal tolerance and can be used more flexibly.
Two Peptides From the Same Lab, Different Mechanisms
Semax and Selank share an origin — both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, both are approved as prescription medications in Russia, and both use intranasal delivery to bypass the blood-brain barrier. But their mechanisms are almost mirror images of each other.
Semax activates. It drives dopaminergic and serotonergic systems, upregulates BDNF, and enhances prefrontal cognitive performance. It is a tool for cognitive output.
Selank calms. It enhances GABA-A function, modulates the enkephalin system, and reduces cortisol and anxiety. It is a tool for cognitive environment.
This complementarity is why they work better together than either alone.
Semax: The BDNF Activator
ACTH (adrenocorticotropic hormone) has a fragment — ACTH(4-7) — that produces cognitive effects independently of its adrenal-stimulating properties. Semax is a synthetic analogue of this fragment with modifications that extend its stability and CNS activity without the cortisol elevation that full ACTH would produce.
Primary mechanism — BDNF upregulation: Semax modulates expression of the neurotrophin genes BDNF and NGF. In rats, a single dose changed BDNF and NGF transcription in the hippocampus, frontal cortex and retina, with the direction depending on region and time point — BDNF expression rising in the frontal cortex early and in the retina by 90 minutes. BDNF is the master regulator of neuroplasticity — synaptic strengthening, new connection formation, and neuronal survival. It is the molecular substrate of learning.
[1]Elevated BDNF means:
- New neural connections form more readily during learning
- Existing synapses strengthen more efficiently
- Neurons are more resistant to stress-induced apoptosis
Secondary mechanism — dopaminergic enhancement: Semax increases dopamine receptor sensitivity in the prefrontal cortex, producing the focus, motivation, and executive function improvements users report. Unlike direct dopaminergic stimulants (amphetamine), this is receptor sensitisation rather than massive dopamine release — no crash, no significant cardiovascular stimulation.
Neuroprotection: In rat models of cerebral ischaemia-reperfusion, Semax reduced ischaemic damage and shifted brain protein and gene expression towards a protective profile, including neurotrophins and their receptors. It is registered in Russia for use in ischaemic stroke, which is where most of the published clinical evidence originates.
[3]Selank: Anxiolysis Without Cost
The defining advantage of Selank over conventional anxiolytics is what it doesn't do:
| Property | Selank | Benzodiazepines | SSRIs |
|---|---|---|---|
| Anxiolytic effect | Yes | Yes | Yes (delayed) |
| Cognitive impairment | No | Yes | Sometimes |
| Dependence | None reported | Significant | Minimal |
| Withdrawal | None | Severe | Mild-moderate |
| BDNF effect | Upregulates | Downregulates | Variable |
| Onset | 20-30 min | 20-40 min | 2-4 weeks |
Selank appears to act on GABAergic transmission by a route other than the benzodiazepine binding site. In rat frontal cortex, Selank changed the expression of genes involved in GABAergic neurotransmission — including GABA receptor subunits and transporters — in a pattern correlating with the effect of GABA itself, rather than acting as a benzodiazepine-site ligand. That difference is the proposed reason it lacks the sedation, cognitive impairment and dependence liability of benzodiazepines, though the receptor-level mechanism is still not fully characterised.
[2]The Flow State Stack Protocol
See the complete Flow State Stack Protocol for full details. In brief:
Step 1 (T-30 min): Alpha-GPC 300mg oral, empty stomach — builds acetylcholine substrate
Step 2 (T-10 min):
- Semax 0.6mg intranasal (1-2 drops per nostril, 0.1% solution)
- Selank 0.5mg intranasal (1-2 drops per nostril, 0.15% solution)
- Tilt head back slightly, sniff gently after each drop
Effects window: Peak cognitive state typically 30-90 minutes after administration, sustained for 3-4 hours.
Cycling to Prevent Tolerance
Semax: Tolerance to the BDNF-upregulating effects develops with daily use. Cycle 2-4 weeks on, 1-2 weeks off. Some users report that off-cycle periods show sustained BDNF elevation — a potential cumulative neuroprotective effect.
Selank: Significantly less tolerance development. Many users maintain consistent effects with daily use. A 4 weeks on, 1 week off cycle is recommended for long-term protocols, but flexibility is greater than with Semax.
Sourcing Note
Semax and Selank are sold as nasal sprays. The concentrations are:
- Semax: typically 0.1% (1mg/ml) solution
- Selank: typically 0.15% (1.5mg/ml) solution
Store in refrigerator. Typical shelf life after opening: 4-6 weeks refrigerated. Both are available from Eastern European supplement suppliers — verify COA for peptide sequence confirmation.
Scientific References
- [1]Shadrina M, Kolomin T, Agapova T, et al.. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action — Journal of Molecular Neuroscience (2010)Oxford 4PMID 19662538
- [2]Volkova A, Shadrina M, Kolomin T, et al.. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission — Frontiers in Pharmacology (2016)Oxford 4PMID 26924987
- [3]Sudarkina OY, Filippenkov IB, Stavchansky VV, et al.. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH((4-7))PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion — International Journal of Molecular Sciences (2021)Oxford 4PMID 34201112
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.